ESRRA and osteosarcoma: It has been reported that ACY1215, an HDAC6 inhibitor, raised the acetylation of K129 in estrogen-related receptors α (ERRα), inducing ubiquitination and degradation of ERRα and restoring chemosensitivity of osteosarcoma cells to cisplatin [194].